Results 131 to 140 of about 6,088 (209)

Pleiotropic Roles of FBXO11 in Tumorigenesis: Implications for Targeted Therapy

open access: yesCancer Science, EarlyView.
This complex comprises of scaffold CUL1, SKP1, RBX1 and FBXO11 receptor. The substrate is phosphorylated by specific kinase enzyme and recognized by the substrate recognition domain. FBXO11 targets numerous substrates for ubiquitination and degradation, FBXO11 substrates mainly include Snail, ZEB1, p53, BCL6, CDT2, CIITA, Cdc25a, hnRNPA2B1, SAMD1 and ...
Yuqi Zhang   +6 more
wiley   +1 more source

Pirtobrutinib in Richter syndrome: Outcomes from the named patient programme in Italy

open access: yes
British Journal of Haematology, EarlyView.
Isacco Ferrarini   +19 more
wiley   +1 more source

Real‐World Safety and Efficacy of Pola‐R‐CHP in Previously Untreated DLBCL: POLASTAR Interim Analysis of 500 Patients

open access: yesCancer Science, EarlyView.
In this analysis of a diverse cohort of 500 patients with previously untreated DLBCL in a real‐world clinical setting, Pola‐R‐CHP demonstrated high response rates at end‐of‐treatment, which were consistent among the overall population, in patients > 80 years and regardless of International Prognostic Index status and cell of origin subtypes.
Takahiro Kumode   +21 more
wiley   +1 more source

Mitochondrial Morphology Dynamics Remodel Metabolism and Affect TKI Sensitivity in EGFR‐Mutated Lung Cancer

open access: yesCancer Science, EarlyView.
TKI treatment promotes mitochondrial fission and metabolic reprogramming toward oxidative phosphorylation in residual EGFR‐mutant lung cancer cells. Targeting this metabolic vulnerability restores TKI sensitivity and provides a promising strategy to overcome acquired resistance.
Yu Zhao   +8 more
wiley   +1 more source

Independent validation of the International Metabolic Prognostic Index (CAR‐IMPI) in patients with aggressive diffuse large B‐cell lymphoma treated with CAR‐T

open access: yes
British Journal of Haematology, EarlyView.
Eugenio Galli   +11 more
wiley   +1 more source

SLAMF6 Enhances the Efficacy of Anti‐PD‐L1 Immunotherapy in CRC Through the STAT1/CXCL10 Signaling Axis

open access: yesCancer Science, EarlyView.
SLAMF6 recruits SHP‐2 to activate STAT1, upregulates CXCL10 and PD‐L1, promotes CD8+T cell infiltration, and enhances the efficacy of anti‐PD‐L1 therapy. ABSTRACT As a T‐cell receptor co‐stimulatory protein, signaling lymphocyte activation molecule family 6 (SLAMF6) is a member of the immune cell activating receptor family and is expressed on T cells ...
Yu Wu   +8 more
wiley   +1 more source

High ZFP36 Family Expression in Exhausted T Cells Is Associated With Impaired Antitumor Effector Function

open access: yesCancer Science, EarlyView.
Hypoxia induces ZFP36 family expression in exhausted CD8+ T cells, promoting the decay of AU‐rich effector cytokine mRNAs and suppressing TNF, IL2, and IFNG expression, thereby potentially contributing to impaired antitumor effector function. ABSTRACT Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by reinvigorating antitumor ...
Li Zhu   +12 more
wiley   +1 more source

A Novel Plasma Biomarker hsa_circ_0080018 Drives DLBCL Progression via M2 Polarization of Tumor‐Associated Macrophages

open access: yesCancer Science, EarlyView.
The proposed mechanistic model in this study. ABSTRACT Noncoding RNAs, including circular RNAs (circRNAs), have been demonstrated to play vital roles in tumorigenesis. Uncovering the functions of circRNAs in tumorigenesis and their underlying regulatory mechanisms may suggest new approaches to the development of novel diagnostic and therapeutic ...
Yanfeng Liu, Yanan Gao, Chuanli Zhao
wiley   +1 more source

Evolution of CAR‐T Therapy: Functional Engineering, Manufacturing Innovation, and Future In Vivo Strategies

open access: yesCancer Science, EarlyView.
CAR‐T therapy is evolving across four interconnected dimensions: functional engineering, manufacturing innovation, alternative cell sources, and in vivo CAR programming. Together, these advances address limitations in therapeutic efficacy, safety, manufacturing complexity, scalability, and accessibility, providing complementary paths toward the next ...
Yukimi Sakoda
wiley   +1 more source

Squamoid Eccrine Ductal Carcinoma: Case Series of a Rare, Potentially Aggressive Skin Cancer Associated With Immunosuppression

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Squamoid Eccrine Ductal Carcinoma (SEDC) is a rare cutaneous adenexal carcinoma first described in 1997. It has distinct biphasic features on histology which commonly result in misdiagnosis as Bowen disease or cutaneous squamous cell carcinomas (cSCC) if diagnostic skin biopsies are too superficial. This may lead to a delay in diagnosis. It is
Xiang Li Tan   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy